Precipio Announces Q1 2026 Financial Results May 14, 2026 05:00PM
Management team’s 2025 market-based Options have vested May 13, 2026 05:00PM
Precipio Announces Q1-2026 Shareholder Update Call May 6, 2026 05:00PM
Precipio Announces Q4 and year-end 2025 Shareholder Update Call Mar 12, 2026 05:00PM
Precipio Announces Publication of a Joint Study with Memorial Sloan-Kettering Cancer Center Highlighting Its Cutting-Edge Bloodhound BCR::ABL1 Assay Mar 10, 2026 09:00AM
View Older Stories

Feb 25, 2026 09:30AM Precipio 2025 (Unaudited) Revenues Grew to $24.0M, a 30% Increase Year-Over-Year
Jan 15, 2026 09:00AM Precipio Takes Major Steps Toward a Clean Balance Sheet
Dec 5, 2025 10:00AM Precipio to Showcase its BCR::ABL1 panel at 2025 ASH (American Society of Hematology) Meeting
Nov 14, 2025 04:30PM Precipio Announces its Q3-2025 Financial Results
Nov 4, 2025 05:00PM Precipio Announces Q3-2025 Shareholder Update Call
Sep 2, 2025 10:01AM Precipio terminates at-the-market equity offering program
Sep 2, 2025 10:00AM Precipio Terminates Its ATM
Aug 13, 2025 05:00PM Precipio Announces its Q2-2025 Financial Results
Jul 31, 2025 04:30PM Precipio Announces Q2-2025 Shareholder Update Call
Jul 11, 2025 04:30PM Precipio amends warrant agreement to reduce share dilution
Jul 11, 2025 04:30PM Precipio Enters Into Agreement With Warrant Holder To Exercise Majority Of Warrants As Cashless
Jun 16, 2025 12:00PM Precipio is requesting Shareholders/Brokers vote today to avoid costly adjournment and rescheduling of Annual Shareholders Meeting
May 14, 2025 05:00PM Precipio Announces its Q1-2025 Financial Results
May 1, 2025 05:00PM Precipio Announces Q1-2025 Shareholder Update Call
Mar 17, 2025 05:00PM Precipio Announces Q4 and year-end 2024 Shareholder Update Call
Feb 25, 2025 09:30AM Precipio Achieves Key Q4-2024 Financial Goals: Positive Adjusted EBITDA and Positive Cash Flow (unaudited)
Jan 16, 2025 05:00PM Precipio grants senior management performance-based awards instead of traditional time-vested ESOPs
Nov 6, 2024 05:00PM Precipio Announces Q3-2024 Shareholder Update Call
Oct 8, 2024 10:00AM Precipio Expands Bloodhound™ MPN Panel by Adding CALR Mutation Subtyping
Sep 6, 2024 04:00PM Precipio Announces Employee Stock Option Plan Repricing
Aug 15, 2024 05:00PM Precipio Announces Q2-2024 Shareholder Update Call
Jul 25, 2024 09:00AM Precipio Reports $0.3M cash generated by operations (unaudited) in Q2-2024, as the company advances towards breakeven
Jul 17, 2024 09:00AM Precipio Reports $4.4M for Q2-2024 (unaudited) Revenues, a leap of 30% from Q1-2024
Jun 13, 2024 04:00PM Precipio Inc. Announces Adjournment of Annual Meeting of Stockholders
Jun 12, 2024 04:00PM Precipio (PRPO) requesting Shareholders/Brokers vote today to avoid adjournment and rescheduling of AGM
Jun 12, 2024 04:00PM Precipio is requesting Shareholders/Brokers vote today to avoid costly adjournment and rescheduling of Annual Shareholders Meeting
Jun 12, 2024 09:04AM Precipio (PRPO) Provides Status Update on Current Business Matters
Jun 12, 2024 09:00AM Precipio Provides Status Update on Current Business Matters
May 6, 2024 05:00PM Precipio Secures a short-term $500K Credit Facility
Mar 25, 2024 05:00PM Precipio Announces Year end 2023 Shareholder Update Call
Feb 13, 2024 10:00AM Precipio to Report $15.2M for FY-2023 (unaudited) Revenues, an increase of 60% YoY
Feb 6, 2024 10:01AM Precipio (PRPO) and Cardinal Health Sign Distribution Agreement for its HemeScreen Portfolio of Molecular assays for Cancer
Feb 6, 2024 10:00AM Precipio and Cardinal Health Sign Distribution Agreement for its HemeScreen® Portfolio of Molecular assays for Cancer
Nov 16, 2023 05:00PM Precipio Announces Q3-2023 Shareholder Update Call
Oct 18, 2023 09:00AM Precipio to Report $4.5M Q3-2023 Revenues, Double From Q3-2022
Oct 3, 2023 10:00AM Precipio’s Q3 Cash Burn From Operations (unaudited) Declines 59% YoY, from $2.5M in Q3-2022 to approximately $1M in Q3-2023
Sep 28, 2023 09:00AM Precipio Continues to Sign New HemeScreen™ Customers
Sep 25, 2023 11:00AM Precipio (PRPO) Reduces Product Revenue Result Needed for Cash Flow Breakeven
Sep 25, 2023 11:00AM Precipio Reduces Product Revenue Result Needed for Cash Flow Breakeven
Sep 13, 2023 09:30AM Precipio's (PRPO) Pathology Division Exceeds Breakeven Revenues in August, Four Months Ahead of Plan
Sep 13, 2023 09:30AM Precipio’s Pathology Division Exceeds Breakeven Revenues in August, Four Months Ahead of Plan
Aug 10, 2023 05:00PM Precipio Announces Q2-2023 Shareholder Update Call
Aug 8, 2023 09:00AM Precipio Launches Its Much-Anticipated Quantitative BCR-ABL 2.0 Panel
Aug 3, 2023 09:00AM Precipio’s Operational Efficiency Measures Continue To Reduce Cash Burn And Move The Company Towards Breakeven
Aug 1, 2023 09:00AM Precipio Unaudited Q2-2023 Revenues Show combined increase of 25% over Q1-2023
Jun 14, 2023 09:49AM Precipio’s Omnia™ Methodology Enables Diagnosis of MDS With Peripheral Blood Instead of Bone Marrow Biopsy
Jun 13, 2023 09:00AM Precipio Enters into Collaboration with Prestigious New York-based Institution to Develop Revolutionary Brain Tumor Panel using HemeScreen® Technology
Jun 8, 2023 08:31AM Precipio (PRPO) Prices 4.13M Share Offering at $0.45/sh
Jun 8, 2023 08:30AM Precipio, Inc. Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private Placement
Jun 7, 2023 09:30AM Projected cash burn reduced by $1.5 million annually from Three Operational Efficiency Projects
View Older Stories